Compare National Energy Services Reunited Corp Ordinary Shares (NESR) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Energy Services Reunited Corp Ordinary Shares vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? National Energy Services Reunited Corp Ordinary Shares trades at $19.71 (market cap $2.12B), while Royalty Pharma plc Class A Ordinary Shares trades at $59.03 (market cap $25.18B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 11.9× National Energy Services Reunited Corp Ordinary Shares's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while National Energy Services Reunited Corp Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold National Energy Services Reunited Corp Ordinary Shares for 0 Days and Royalty Pharma plc Class A Ordinary Shares for 6 Days on average.
| NESR | RPRX | |
|---|---|---|
Market Cap | $2.12B | $25.18B |
Volume | 3,257,316 | 3,399,248 |
Sector | Energy | Health |
52-Week High | $36.31 | $63.96 |
52-Week Low | $10.41 | $36.18 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $2.24B | $32.42B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NESR trades at $21.03, up 0.62% today, with neutral technical signals and strong fundamental momentum. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.44 exceeding expectations by 25%. Revenue growth remains robust, driven by Middle East operations including the Jafurah gas field expansion. Analyst sentiment is overwhelmingly positive with 83% buy ratings and a consensus price target of $41.80, representing nearly 100% upside potential.
The outlook remains favorable with projected revenue growth to $1.6B in 2026 and net profit doubling to $93M. Key risks include execution pressure from premium valuation and regional geopolitical uncertainties. The recent lithium extraction deal with Saudi Aramco provides additional growth optionality, though capital demands remain elevated. Current levels offer attractive entry for growth-oriented investors despite technical neutrality.
Royalty Pharma (RPRX) trades at $56.57, down 2.09% on the day, with a bullish technical signal and strong fundamentals. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue and net income show steady growth, supported by a high gross profit margin of 89.38%. Analyst consensus is unanimously bullish with a $63.33 price target.
The outlook remains positive given earnings momentum and strategic capital deployment, though risks include biopharma policy shifts and reliance on partner drug performance. The stock offers exposure to a diversified portfolio of blockbuster drugs with minimal operational risk, but investors should monitor upcoming earnings and broader sector dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About National Energy Services Reunited Corp Ordinary Shares
National Energy Services Reunited Corp (NESR) is a Houston-based oilfield services company that provides drilling, evaluation, and production services, including hydraulic fracturing, cementing, coiled tubing, and directional drilling, to oil and gas operators. It focuses primarily on markets across the Middle East, North Africa, and Asia Pacific.
Read more on NESR →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
